Miromatrix and their bioengineered pig-human hybrid organs 🐷The set up for a pump seems to be falling nicely into place, cheap, small cap, descent into oblivion, interesting tech, “undiscovered gem” feeling.
The volume is dastardly and it could still fall sub $2 before making a comeback.
They may pull a card out of their sleeve tomorrow at CareDx’s Xenotransplantation Innovation Day however it seems unlikely. It is probably a better idea to wait for news on the initiation of the phase I trials for their external liver assist program. Around that time if there is an uptick in social media buzz we may very well be in for a good ol’ pump, probably followed by an offering to fill the coffers if the stock price gains permit.
MIRO
MIRO Miromatrix Medical Price TargetMiromatrix Medical Inc. engages in the development of biological human organs to solve the chronic shortage of transplantable organs.
114,000 people in the U.S. are waiting for a life-saving organ transplant, and more than half will die due to a lack of available organs.
Miromatrix Medical trial is expected to begin in the second half of 2022 and will assess the function of a bioengineered liver in humans via an external application.
if it succeeds, the opportunity to buy the stock at these prices will be history.
The Market Cap of MIRO is just 214.74Mil
On 7/19/2021 Craig Hallum brokerage Initiated Coverage with a Buy rating and a $22.00 price target
